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PRESCRIPTION DRUG SYSTEMS AND
PRICE CONTROL IN CANADA
Robert S. Nakagawa ∗
INTRODUCTION
This Article presents a brief overview of the regulation of
prescription drugs in Canada. Part I provides an overview and
the context of the environment in which the system operates;
Part II describes the responsibilities of the federal government;
Part III reviews the national initiatives that have been undertaken
cooperatively between the federal and provincial/territorial
governments; and Part IV describes the responsibilities of the
provincial governments.
I. OVERVIEW AND CONTEXT
With a relatively small population of 33.1 million people
inhabiting 9,984,670 square kilometers (nearly 4 million square
miles), Canada is the world’s 38th most populous country 1 and
the second largest. 2 It is a constitutional monarchy with two
∗
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1
Central
Intelligence
Agency,
The
World
Factbook,
https://www.cia.gov/cia/publications/factbook/rankorder/2119rank.html (last
visited Apr. 12, 2007).
2
Central Intelligence Agency, The World Factbook, https://cia.gov/cia/
publications/factbook/geos/ca.html (last visited Apr. 12, 2007).
3
Gregory P. Marchildon, Health Systems in Transition: Canada, WHO
Regional Office for Europe on behalf of the European Observatory on Health
Systems and Policies 8 (2005), available at http://www.euro.who.int/
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constitutionally recognized orders of government: the federal
government, and the provinces and territories.3 The country is
divided into 10 provinces and three territories. With an average
life span of 79.9 years, Canadians live slightly longer than
Americans, whose average life span is 77.5 years, and spend
significantly less on health care (9.9 percent versus 15.3 percent
of GDP).
Canadians place a high degree of importance on health care.
The Commission on the Future of Health Care in Canada (the
Romanow Commission) identified Medicare as “a defining
aspect of our citizenship and an expression of social cohesion.” 4
Public sources fund 70 percent of the costs of the health care
system in Canada, while the remaining 30 percent comes from
the private sector. 5
Drug therapy is the cornerstone of modern medical care in
Canada. The number of drugs available to treat, diagnose and
prevent disease has increased steadily over the last 30 years. As
the number of available drugs has increased, so has their use.
The Romanow report found that 300 million prescriptions, an
average of 10 per person, are filled in Canada annually. 6 Drug
expenditures have followed suit. In 1985, the total expenditure
on drugs in Canada was $3.8 billion; this figure was forecast to
hit $24.8 billion by 2005. 7

Document/E87954.pdf.
4
Roy J. Romanow, Q.C., Building on Values: The Future of Health
Care in Canada xxi (2002), available at http://www.hcsc.gc.ca/
english/pdf/romanow/pdfs/HCC_Final_Report.pdf.
5
Exploring the 70/30 Split: How Canada’s Health Care System is
Financed. Canadian Institute for Health Information, Ottawa, Ontario 3
(2005), available at http://secure.cihi.ca/cihiweb/products/FundRep_EN.pdf.
6
Romanow, supra note 4 at 191.
7
Drug Expenditures in Canada 1985 to 2004. Canadian Institute for
Health Information, Ottawa, Ontario 11 (2005), available at http://dsppsd.pwgsc.gc.ca/Collection/H115-27-2004E.pdf.
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A. Who Does What?
Federal, provincial, and national structures and programs are
primarily responsible for health care in Canada. National
initiatives involve the cooperation of the federal, provincial, and
territorial governments. The breakdown of federal, national and
provincial responsibilities for prescription drugs is as follows:
Federal
• Approval of new drugs for sale
• Patent drug pricing
National (includes Federal, Provincial and Territorial
Participants)
• Evidence-based drug reviews (through the Common
Drug Review)
• Formulary recommendations (through the Canadian
Expert Drug Advisory Committee)
Provincial
• Drug plan formulary decisions
• PharmaNet Systems
II. FEDERAL GOVERNMENT RESPONSIBILITIES
The federal government’s role in the health system involves:
(1) Setting and administering national principles and
standards for the health care system. For example, the
Canada Health Act requires that medical and hospital
services are provided free of charge to Canadians. The
five principles of the Canada Health Act are public
administration,
comprehensiveness,
universality,
portability and accessibility. Provinces must meet these
criteria in the delivery of health care services in order to
receive full federal contributions. 8
(2) Assisting in the financing of provincial health care
8

CANADA HEALTH ACT OVERVIEW (November 25, 2002),
http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/2002/2002_care-soinsbk4_e.html
(last visited January 14, 2007).
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services through fiscal transfers (there were $32.5
billion in cash and tax transfers during 2006-2007). 9
(3) Delivering direct health services to specific groups
including veterans, native Canadians, persons living on
reserves, military personnel, inmates of federal
penitentiaries and the RCMP. Their drug plans cover
1.2 million Canadians.
(4) Health protection, disease prevention and health
promotion.
(5) Regulating the safety, efficacy and quality of drugs. The
Therapeutic Products Directorate is responsible for
ensuring that prescription drugs marketed in Canada are
safe and effective. The Directorate is committed to
ensuring that decisions made are evidence-based and
timely. 10
(6) The price of patented medicines (through the Patented
Medicines Prices Review Board).
While not its primary role, the federal government is
responsible for the delivery of health care services provided to
the military, First Nations, corrections, and veterans groups.
A. Federal Price Controls 11
Price control of patented medicines is the responsibility of
the Patented Medicines Prices Review Board (PMPRB). The
PMPRB is an independent body created by Parliament in 1987
under the Patent Act. It was established at the same time that
patent protection was extended for pharmaceuticals as a safety
net to ensure that Canadians were not paying an excessive price
9

GOVERNMENT OF CANADA: DEPARTMENT OF FINANCE, CANADA
HEALTH TRANSFER (FEDERAL TRANSFERS TO PROVINCES AND TERRITORIES,
May 2006), http://www.fin.gc.ca/FEDPROV/chte.html (last visited Jan. 13,
2007).
10
GOVERNMENT OF CANADA: HEALTH, DRUGS AND HEALTH,
http://www.hc-sc.gc.ca/dhp-mps/index_e.html (last visited Jan. 14, 2007).
11
GOVERNMENT OF CANADA: PATENT MEDICINE PRICES REVIEW BOARD,
WELCOME!, http://www.pmprb-cepmb.gc.ca/english/home.asp?x=1 (last
visited Jan. 13, 2007).
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at the same time that manufacturers enjoyed a longer duration of
market exclusivity. The PMPRB is a quasi-judicial tribunal that
sets price guidelines and has the power to roll back prices that
are deemed excessive. Figure 1 shows the amount of
prescription drug sales in Canada from 1993 to 2005.
Figure 1
16
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It should be noted that the PMPRB only has jurisdiction over
patented prescription drugs, and as such does not have the
authority to regulate non-patented drugs including generic drugs,
prices charged by wholesalers or retailers, or pharmacists’
professional fees. Rather, the PMPRB determines whether a
price set by a manufacturer is excessive by employing the
following guidelines:
• Existing patented drug prices cannot increase by more
than the Consumer Price Index;
• New patented drug prices are limited so that the cost
of therapy is in the range of the cost of therapy for
existing drugs used to treat the same disease; and
• Breakthrough drug prices are limited to the median of
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the prices for the same drugs charged in other
specified industrialized countries that are set out in
the Regulations under the Patent Act (France,
Germany, Italy, Sweden, Switzerland, the U.K. and
the U.S.). The determination of “breakthrough” is
made by an expert advisory committee established by
the PMPRB.
The impact of the PMPRB on patented drug prices in
Canada relative to the defined comparator countries is shown in
Figure 2. The ratio indicated along the y-axis represents the
ratio of foreign prices to Canadian prices for patented drugs in
the years 1987, 1997 and 2005. The relative price of
prescription drugs in Canada has been reduced from 73 percent
to 58 percent of the U.S. price. It is clear that the U.S. pays the
highest price for prescription drugs among the comparator
countries.
156
172
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Increases in health spending relative to increases in other
publicly funded services in Canada are a growing concern. In
British Columbia, the Ministry of Health spent almost 42
percent of the provincial budget in the fiscal year of 2004-2005
on health care. 12 Average annual increases in expenditures have
12
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been approximately 8 percent per year, while Provincial
revenues are anticipated to grow by approximately 3 percent per
year. This 5 percent difference between revenues and
expenditures is a significant concern to the government of
British Columbia. At that rate, health expenses have the
potential to consume all provincial expenditures other than
education by the fiscal year 2018. 13
Prescription drug expenses in British Columbia are
increasing at an even greater rate. Over the last five years, the
average increase in spending has been approximately 9 percent
per year. This could be considered a worthwhile investment in
health if the drugs funded generally represented significant
advances in therapy, and resulted in better patient outcomes
(reduced physician visits, hospitalizations and emergency
department visits). However, this is not the case. While some
drugs are true therapeutic breakthroughs, most of them are not.
Prescrire, 14 a French publication, is one of the few publications
that places a value on new medicines, rating them on a scale
ranging from “not acceptable” to “bravo.” Figure 3 shows that
over the period 1981 to 2005, of 3,122 reviewed drugs or
indications, more than two-thirds of them were “nothing new.”
Only 2 percent were considered to be real advances, and a mere
seven drugs (0.22 percent) were considered to be worthy of a
“bravo” rating. 15

CONVERSATION ON HEALTH, http://www.bcconversationonhealth.ca/428/368/
(last visited Jan. 13, 2007).
13
PROVINCE OF BRITISH COLUMBIA: MINISTRY OF FINANCE, ECONOMIC
AND FISCAL UPDATE (Sept. 15, 2006), http://www.fin.gov.bc.ca/qrtrpt/qr06/q1powerpoint.pdf (last visited Jan. 11, 2007).
14
PRESCRIRE INTERNATIONAL, available at http://www.prescrire.org/
signature/productions/international.php.
15
A review of new drugs in 2004: Floundering innovation and increased
risk-taking, PRESCRIRE INTERNATIONAL, April 2005, vol.14, n. 76 pp. 68-73.
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Figure 3
New Products Ratings 1981–2005
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Based on La Revue Prescrire with 3,122 drugs or new indications; does
not include over-the-counter medications or product line extensions
Prescrire Rating Scale:
Bravo—The drug is a major therapeutic innovation in an area where
previously no treatment was available.
A Real Advantage—The product is an important therapeutic innovation
but has certain limitations.
Offers an Advantage—The product has some value but does not
fundamentally change the present therapeutic practice.
Possibly Helpful—The product has minimal additional value, and should
not change prescribing habits except in rare circumstances.
Judgment Reserved—The editors postpone their judgment until better
data and a more thorough evaluation of the drug are available.
Nothing New—The product may be a new molecule but is superfluous
because it does not add to the clinical possibilities offered by previous
products available. In most cases it concerns a me-too product.
Not Acceptable—Product without evident benefit but with potential or
real disadvantages.
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III. NATIONAL INITIATIVES
The following sections describe the national initiatives,
including the National Pharmaceuticals Strategy and the pooling
of resources for drug plan reviews through the Common Drug
Review and the Canadian Expert Drug Advisory Committee.
A. The National Pharmaceuticals Strategy 17
First Ministers (the Prime Minister of Canada and the
Premiers of each of the provinces and territories) agreed to
implement a 10-year plan to strengthen health care in Canada.
The National Pharmaceuticals Strategy is an important part of
this plan. The following nine elements are involved in this
strategy:
• Develop, assess and cost options for catastrophic
pharmaceutical coverage;
• Establish a common National Drug Formulary for
participating jurisdictions based on safety and cost
effectiveness;
• Accelerate access to breakthrough drugs for unmet health
needs through improvements to the drug approval process;
• Strengthen evaluation of real-world drug safety and
effectiveness;
• Pursue purchasing strategies to obtain best prices for
Canadians for drugs and vaccines;
• Enhance action to influence the prescribing behaviour [sic]
of health care professionals so that drugs are used only
when needed and the right drug is used for the right
problem;
• Broaden the practice of e-prescribing through accelerated
development and deployment of the Electronic Health
Record;
• Accelerate access to non-patented drugs and achieve
17

FEDERAL/PROVINCIAL/TERRITORIAL MINISTERIAL TASK FORCE,
NATIONAL PHARMACEUTICALS STRATEGY PROGRESS REPORT 4 (2006),
available at http://www.hc-sc.gc.ca/index_e.html.
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international parity on prices of non-patented drugs; and
• Enhance analysis of cost drivers and cost-effectiveness,
including best practices in drug plan policies.
In September 2006, a progress report was released. 18 The
report outlined the current status and progress of each of the
NPS elements as well as highlighting the priority work for the
next year. In addition, there was a commitment by the
governments to involve stakeholders to a greater degree in the
development of initiatives.
B. Drug Plan Formulary Decisions
There are 19 publicly funded drug plans in Canada: one for
each of the 10 provinces and three territories, as well as six
federal plans. Beneficiaries under each of these plans are
determined by the jurisdiction. While most of the plans provide
coverage for seniors and low-income families, some are more
universally available with varying degrees of deductibles and copays. Until 2002 each plan undertook its own review of the
drug’s therapeutic and economic profile. 19
C. The Common Drug Review 20
In 2002, a Common Drug Review (CDR) process was
established to provide a single drug review to serve as the basis
for drug formulary decisions in each of the drug plans.
Manufacturers of public drug plans submit requests for drugs to
be reviewed by the CDR for new drugs that have been approved
for sale in Canada by Health Canada, and have not previously
been available. 21 The staff prepares a common drug review
18

Id.
Health Canada, Common Drug Review, http://www.hc-sc.gc.ca/hcssss/pharma/mgmt-gest/cdr-emuc/index_e.html (last visited Mar. 22, 2007).
20
Canadian Agency for Drugs and Technology in Health, Canadian
Expert Drug Advisory Committee. http://www.cadth.ca/index.php/en/
cdr/committees/cedac (last visited Mar. 22, 2007).
21
The submission requirements are available at http://www.cadth.ca/
media/cdr/process/CDR_SubmissionGuidelines_2006_ Sept20.pdf.
19
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document based on the submission and independent literature
searches. The drug manufacturer then comments on the review
before it is finalized.
D. Canadian Expert Drug Advisory Committee 22
The Canadian Expert Drug Advisory Committee (CEDAC)
is an 11-member independent advisory body with expertise in
drug therapy and drug evaluation, and has two new public
members as of the fall of 2006. The CEDAC is responsible for
reviewing the final CDR and developing formulary
recommendations for consideration by each of the public drug
plans. Listing recommendations are provided confidentially to
the drug plans and the manufacturer under embargo to allow for
comment. The final recommendations, along with the basis for
said recommendations, are posted on the website.
IV. PROVINCIAL GOVERNMENT RESPONSIBILITIES
In general, the provincial governments are responsible for
managing and delivering health care services within their
jurisdiction, which involves planning, financing, and evaluation
and provision of hospital care, physician and allied health care
services, as well as the regulation of the practices of the health
professions. Although payment for prescription drugs is not
required under the Canada Health Act, every province offers
some form of drug insurance to their citizens. The beneficiary
and drug coverage parameters vary widely among the plans.

22

Government of British Columbia PharmaCare, PharmaNet,
http://www.healthservices.gov.bc.ca/pharme/pharmanet/netindex.html
(last
visited Mar. 22, 2007).
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A. Drug Plan Decisions
Each of the drug plans make listing and coverage decisions
based on:
• CEDAC’s recommendation
• Their mandates, priorities and resources
• Generic price limits and drug substitution
requirements
• The availability of therapeutic reference-based pricing
• The availability of policies that ensure that more
expensive drugs are only provided when predetermined criteria (Special Authorization, Prior
Authorization) are met
B. PharmaNet—Provincial Pharmacy Network 23
British Columbia has one of the most comprehensive
pharmaceutical databases in the world. Since 1995, pharmacists
have been required by law to enter all community prescriptions
into the database. This legislation was targeted at ensuring better
patient safety by reducing preventable adverse events and
hospital admissions by the early identification of drug
interactions, allergies and other therapeutic problems by the
pharmacist. It was felt that a pharmacist would not be able to
safely dispense a prescription drug without access to a complete
drug profile for the patient. The current drug database now
includes all prescriptions dispensed in British Columbia
pharmacies since 1995.
In addition to these clinical benefits, the PharmaNet system
allows pharmacists to monitor for prescription drug abusers and
prevent prescription fraud. Work is currently underway to
establish a pan-Canadian standard for drug information systems
to support the development of PharmaNet systems throughout
23

Canada
Health
Infoway,
Drug
Information
Systems,
http://www.infoway-inforoute.ca/en/WhatWeDo/DrugsInfo.aspx (last visited
Mar. 22, 2007).
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Canada. This is being developed with support from Canada
Health Infoway and supported by both the federal, provincial
and territorial governments. 24
CONCLUSION
Health care in Canada is provided largely through support
from the federal, provincial and territorial governments. The
federal government is responsible for the approval of new drugs
for sale in Canada as well as the regulation of patent drug
pricing. Provincial governments are responsible for their own
drug plan design and for determination of the drugs for which
they will provide payment. They also operate independent
prescription drug systems, such as PharmaNet, to ensure the
safe and efficient dispensing of prescription drugs.
There are many aspects of the Canadian health care system
that may be of interest to U.S. policy makers. Drug price
regulation for patented medicines could provide more accessible
prescription drugs in the U.S. Cooperation between the federal
and provincial/territorial governments to advance the national
pharmaceutical agenda and share rigorous reviews of new drugs
has been valuable in Canada. Similar cooperation in the U.S.
may provide similar benefits. Finally, government sponsored,
comprehensive electronic prescription databases may provide an
additional element of safety for patients, protecting them from
untoward drug effects resulting from drug interactions or other
sensitivities.

24

Id.

